Business Overview: SIGA Technologies, Inc. (NASDAQ: SIGA)

---

Executive Summary

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company whose business is almost entirely built around a single product: TPOXX® (tecovirimat), an antiviral treatment for smallpox and, following emergency authorizations, related orthopoxviruses such as mpox. SIGA holds FDA approval for both oral TPOXX® (since July 2018) and an intravenous formulation (since May 2022), and has secured additional approvals in the EU, Canada, the UK, and, as of December 2024, Japan.

SIGA's customer base is overwhelmingly government: the U.S. Strategic National Stockpile (via BARDA procurement contracts) and a growing list of international governments building their own biodefense reserves. With only 46 full-time employees as of early 2025, SIGA is a lean, royalty-like business built on being essentially the only FDA-approved oral smallpox antiviral on the market.

---

1. Core Business Model & How They Work

Contract Manufacturing (CMOs — SIGA owns no plants)
        ➡️ Regulatory Approval & Stockpile Qualification (FDA, EMA, international)
        ➡️ Government Procurement Contracts (BARDA / Strategic National Stockpile)
        ➡️ International Government Sales (direct + via Meridian Medical Technologies partner)
        ➡️ Delivery & Stockpiling (little to no ongoing consumption — replenishment-driven)

SIGA does not manufacture its own product; it relies entirely on contract manufacturers (CMOs) and focuses its internal resources on regulatory strategy, government relations, and international business development. Revenue is driven by large, lumpy government procurement contracts rather than a conventional patient-demand sales cycle — the core BARDA "19C" contract alone provides for up to roughly $602.5 million in potential payments, of which about $519.6 million had been exercised as of year-end 2024, with the remainder at BARDA's discretion.

---

2. Product Portfolio

Cumulative oral TPOXX® deliveries to the U.S. Strategic National Stockpile reached $396.9 million through year-end 2024. International sales were $23.0 million in 2024 across 13 countries, up from $21.3 million in 2023 across 7 countries — evidence of a widening (if still small) international government customer base. Department of Defense sales added roughly $10 million in 2024.

---

3. Competitive Landscape

SIGA's competition is less about rival products displacing TPOXX® in the field and more about competing for finite government biodefense budgets and stockpile allocation:

• Emergent BioSolutions — a broader biodefense/public health portfolio company (anthrax, smallpox vaccines) that competes for the same BARDA/stockpile dollars, though not with a directly competing oral smallpox antiviral.
• Bavarian Nordic — maker of the JYNNEOS smallpox/mpox vaccine; competes in the same biodefense budget conversations as a preventive (vaccine) rather than therapeutic (antiviral) alternative.
• Government-direct R&D — national biodefense agencies could in theory fund alternative antivirals, but TPOXX®'s existing approvals and stockpile track record are a high bar to displace.

                High Stockpile/Government Reliance
                            |
      SIGA (TPOXX) •        |   • Emergent BioSolutions
                            |
Therapeutic -----------------+----------------- Preventive (Vaccine)
                            |
                            |   • Bavarian Nordic (JYNNEOS)
                            |
                Low Stockpile/Government Reliance

---

4. Strategic Strengths & Risks

Strengths: SIGA effectively holds a first-mover, best-in-class regulatory moat — it is the only company with an FDA-approved oral antiviral specifically for smallpox, now backed by approvals across the EU, Canada, UK, and Japan. This regulatory breadth, built over many years of trials and government engagement, would be extremely costly and slow for a new entrant to replicate. The asset-light manufacturing model (no owned plants) keeps SIGA's cost base lean relative to its government contract revenue.

Risks: Revenue is almost entirely dependent on discretionary government procurement — BARDA's remaining contract options are exercised "at its sole discretion," and contracts can be canceled, making revenue lumpy and unpredictable year to year. SIGA has essentially one commercial product; any safety, efficacy, or stockpile-rotation setback for TPOXX® would be existential rather than diversifiable. The business also depends on continued perceived biodefense/public-health threat (smallpox, mpox) to sustain government purchasing appetite.

---

5. Financial Overview

---

6. Summary Conclusion

SIGA is best understood as a government-contract annuity wrapped around a single, hard-to-replicate regulatory asset: the only FDA-approved oral smallpox antiviral, now cleared across multiple major regulatory jurisdictions. That regulatory moat generates genuinely attractive margins and a lean cost structure, but the business's near-total dependence on discretionary, cancelable U.S. and international government procurement means its biggest forward risk is not competition from a rival drug — it is the pace and size of future BARDA option exercises and international stockpile orders, which SIGA does not control.